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The need of innovative influenza formulations to im-
prove immunogenicity and effectiveness of conventional 
trivalent vaccines, subunit or split non-adjuvanted types, 
in groups of patients at risk of developing severe com-
plications has facilitated the development of interesting 
lines of research in recent years.
Moreover, the interest in the dose-sparing potential and 
the recent availability of innovative injection systems 
has led to a renewed attention in the intradermal (ID) 
administration of influenza vaccines. This new micro-
injection system (Soluvia®, Beckton Dickinson, USA), 
currently the only intradermal device licensed for in-
fluenza vaccines, is a prefilled syringe with a single 
30-gauge needle, 1.5 mm in length, that has a system 
specifically designed to limit the depth of penetration, 
reducing blood vessel and nerve injuries in patients. The 
sensation of injection is claimed to be almost impercep-
tible to the patient. The device is designed to protect the 
needle after injection, reducing risk of injury for health 
care workers.
In recent years, numerous studies have been conducted 
with the aim of assessing the immunogenicity of ID vac-
cines, containing a dose of antigen equal to or lower than 
that contained in the non-adjuvanted intramuscular (IM) 
vaccine (15 μg/Hemagglutinin (HA) strain). The results 
of these studies demonstrate the ability of ID vaccines 
to elicit a good response even at lower doses of anti-
gen, and to determine, at the same dose, a response even 
greater than that of the IM vaccines. This aspect is of 
crucial importance, especially in low-responders after 
IM. In this regard, a recent study of 3,707 subjects aged 
> 60 years, randomized to receive either a preparation 
ID or IM containing 15 μg of antigen demonstrated that 
ID vaccine is more immunogenic of the conventional IM 
vaccine, maintaining a safety profile comparable to the 
vaccine IM [1].
The immunogenicity of an intradermal seasonal influ-
enza vaccine was compared with that of an adjuvanted 
vaccine in the elderly: 795 subjects were randomized to 
receive an ID vaccine or an MF59 adjuvanted IM vac-
cine, both containing 15 μg of HA. The immunogenicity 
and safety of the ID vaccine in the elderly was compara-
ble with that of the adjuvanted vaccine [2].
Recently, a new ID, trivalent, inactivated, seasonal in-
fluenza vaccine (Intanza®, Sanofi Pasteur, France) has 
been available in Europe: two formulations are currently 
available on the market, one for adults aged 18-59 years 
(9 μg/HA strain) and the other for the elderly ≥ 60 years 
(15 μg/HA strain). We carried out an “on field” ran-
domised study in elderly to evaluate the acceptability of 
Intanza® and to compare it to that of a trivalent subunit 
virosomal formulation (Inflexal V®, Berna, Switzerland) 
delivered by IM route.The study showed a good accept-
ability of both the vaccines. As expected, since the ID 
injection is close to the skin surface, an higher bother 
due to redness, itching and induration was observed in 
the ID-group, but it was in a few proportion of subjects 
and its clinical relevance was not meaningful. 
In general, the good profile of immunogenicity, safety 
and tolerability suggests the ID immunization suitable 
for the subjects low-responders to conventional vac-
cines.
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